Semantic Networks in Alcohol Use Disorder Patients: Exploratory Study
NCT ID: NCT05636033
Last Updated: 2025-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60 participants
OBSERVATIONAL
2023-04-19
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A study, conducted in patients with neurological damage, showed that frontal lesions are associated with excessive strength in semantic associations, and difficulties to generate remote associations. This excessive strength in semantic associations could reduce the ability to inhibit automatisms and to adapt to new context.
Objective: The objective of this study is to explore whether and how AUD patients have a different organization of semantic associations than healthy controls, and whether this reorganization influences the alcohol consumption over the months following the withdrawal. The investigators will also explore how it relates to neuropsychological assessment of flexibility, executive functions, and impulsivity. To these purposes, the investigators will use two original verbal tasks (Free Generation of Associates Task, FGAT and Associative Judgment Task, AJT) assessing word associations and allowing the estimation of semantic networks using graph theory, in combination with neuropsychological testing, in AUD patients and in healthy controls.
Methods: This study will include a group of 30 AUD patients and a group of 30 healthy controls. Both groups will be assessed twice, at baseline (T1; early in abstinence for AUD patients) and after a three-month period (T3). For the two groups, T1 and T3 assessments will include the two semantic association tasks (FGAT and AJT). For AUD patients, assessments will also involve neuropsychological testing of impulsivity, flexibility, and attentional bias. Besides, in AUD patients, data about alcohol consumptions will be collected six weeks (T2) and three months (T3) following the baseline assessment to classify patients as relapsers or abstainers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Self-Concept and Autobiographical Memory in Alcohol Use Disorder
NCT06985927
Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)
NCT05677321
Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients
NCT04490330
Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study
NCT02107352
Sleep and Emotional Reactivity in Alcohol Use Disorder
NCT04979507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alcohol use disorder patients
No interventions assigned to this group
Healthy controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Severe alcohol use disorder
* French as mother tongue
* Right-hander
* Patient abstinent from alcohol since 15 to 30 days at the inclusion
* Patient free from benzodiazepine since at least 48hours at the inclusion
* Patient who gave his informed written consent
* Currently in outpatient or inpatient care
For healthy controls
* French as mother tongue
* Right-hander
* Participant who gave his informed written consent
Exclusion Criteria
* Patient under guardianship or under justice safeguard measures
* Patient under measure of therapeutic injunction
* Pregnancy or breastfeeding declared
* Meeting Diagnostic and Statistical Manual 5 (DSM) criteria for substance use disorder other than Tobacco
* Meeting DSM-5 criteria for non substance use disorder
* Patient presenting severe or progressive disease that interfere with experimental tasks, such as neurological diseases (TBI, epilepsy, stoke) , hepatic diseases, cancer, HIV, Hepatitis C Virus (HCV), and unstable psychiatric comorbidities.
For healthy controls
* Participant under guardianship or under justice safeguard measures
* Participant under measure of therapeutic injunction
* Pregnancy or breastfeeding declared
* Meeting DSM-5 criteria for alcohol use disorder
* Meeting DSM-5 criteria for substance use disorder other than Tobacco
* Meeting DSM-5 criteria for non substance use disorder
* Currently under benzodiazepine
* Participant presenting severe or progressive disease that interfere with experimental tasks, such as neurological diseases (TBI, epilepsy, stoke) , hepatic diseases, cancer, HIV, HCV, and unstable psychiatric comorbidities.
30 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexandra Dereux, PH (MD)
Role: PRINCIPAL_INVESTIGATOR
APHP
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fernand Widal Hospital
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01903-40
Identifier Type: REGISTRY
Identifier Source: secondary_id
C22-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.